Common Ground: Both studies address the role of KCC2 and its impact on cognitive functions through its regulation of the excitatory/inhibitory balance in the hippocampus.
Key Differences: The current study focuses on age-related cognitive decline and evaluates the effects of KCC2 pharmacological targeting in elderly populations. The recommended study examines Alzheimer's disease using a transgenic mouse model and assesses the effect of a specific compound, CLP 257, on KCC2 function and expression.
Methodologies: The current study uses behavioral studies in old mice and elderly humans, assessing KCC2 expression via biochemical techniques. The recommended study employs electrophysiological recordings and biochemical techniques to study the transgenic mouse model, also utilizing CLP 257 treatment to restore KCC2 function.
Complementary Aspects: The current study provides evidence for KCC2 modulation in age-related cognitive impairment, while the recommended study adds insights into early-stage neurological dysfunctions in AD and potential therapeutic interventions.
Potential Impact: Combining findings could advance therapeutic strategies targeting KCC2 for both aging-related cognitive decline and early-stage AD.

Scheduled maintenance in progress.